Dae Gon Ha
Stock Analyst at Stifel
(2.79)
# 1,918
Out of 4,749 analysts
48
Total ratings
33.33%
Success rate
2.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $1.31 | +129.01% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $50.23 | +47.32% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $3.96 | -24.24% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $1.44 | +1,011.11% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $10.32 | +520.16% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $159.74 | +37.72% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $48.88 | +35.02% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $43.03 | +195.14% | 2 | May 31, 2024 | |
| ABEO Abeona Therapeutics | Initiates: Buy | $21 | $5.54 | +279.06% | 1 | May 30, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $7.61 | +425.62% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $10.74 | +346.93% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.80 | +542.86% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.64 | +993.75% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $59.43 | -57.93% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $9.58 | +67.01% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $11.60 | +2,356.90% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.12 | +845.63% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.79 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $29.01 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.90 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.41 | +397.93% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $4.23 | +11,497.63% | 2 | Oct 23, 2017 |
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $1.31
Upside: +129.01%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $50.23
Upside: +47.32%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $3.96
Upside: -24.24%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $1.44
Upside: +1,011.11%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $10.32
Upside: +520.16%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $159.74
Upside: +37.72%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $48.88
Upside: +35.02%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $43.03
Upside: +195.14%
Abeona Therapeutics
May 30, 2024
Initiates: Buy
Price Target: $21
Current: $5.54
Upside: +279.06%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $7.61
Upside: +425.62%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $10.74
Upside: +346.93%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $2.80
Upside: +542.86%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.64
Upside: +993.75%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $59.43
Upside: -57.93%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $9.58
Upside: +67.01%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $11.60
Upside: +2,356.90%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $2.12
Upside: +845.63%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.79
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $29.01
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.90
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $2.41
Upside: +397.93%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $4.23
Upside: +11,497.63%